BD Deals & Industry Events
Deals, JVs and industry events reshaping the China pharma landscape.
CSPC and AstraZeneca's Shijiazhuang plant: I could not find the original source for the widely cited terms
What can be verified is a memorandum of understanding from March; what circulates widely is the '51 to 49' of August 5. The two currently don't line up.
Sep 26, 2026 · 14 min read→BD Deals & Industry Events / Manufacturing JVCSPC × AstraZeneca Shijiazhuang biologics manufacturing JV (2026-08-05): an in-depth teardown
This is not a BD deal; it is the 'settlement method' for the previous four BD deals. It turns CSPC from 'someone who sells molecules' into 'a node in AZ's global supply network' — the value and the risk are both in that sentence.
Sep 26, 2026 · 14 min read→BD Deals & Industry Events / CRSwNPKeymed's CM512 meets its Phase 2 endpoints: an announcement without numbers, and a selling point already taken
On August 10, 2026 Keymed announced CM512 met all Phase 2 endpoints in CRSwNP — superior to control on nasal polyp score at 24 weeks — selecting 300 mg Q24W for Phase 3, with no efficacy values disclosed.
Sep 26, 2026 · 20 min read→BD Deals & Industry Events / CD79a×CD19×CD3Forty days after Roche dropped a CD19 TCE, it licensed in another CD19/CD79a trispecific
Simcere Zaiming licensed global rights (Greater China included) of its preclinical CD79a/CD19/CD3 trispecific SIM0660 to Roche — US$75M upfront, US$1.53B headline total — the first of its six out-licenses to give up Greater China entirely.
Sep 26, 2026 · 12 min read→BD Deals & Industry Events / China biotechNine CAR-T Products, Five Years, Three Lanes: From “Can It Be Approved” to “Who Can Deliver”
As of July 2026, counting NMPA marketing approvals, 9 CAR-T products have been approved in mainland China — from axicabtagene ciloleucel (June 2021) to satricabtagene autoleucel (June 2026), the world's first solid tumor CAR-T — forcing the question: when approval is no longer scarce, who can actually deliver a one-batch-at-a-time, million-yuan-priced “living drug”?
Sep 26, 2026 · 53 min read→BD Deals & Industry Events / Clinical governance16 months and 12 months
HG302 and XH-25-002: a technical review and governance reckoning of two child deaths in gene-editing trials
Sep 26, 2026 · 26 min read→BD Deals & Industry Events / BD dealEleven months, US$32.5 million turned into US$382.5 million
Hengrui sold HRS-1893's ex-China rights to a newly founded company. Eleven months later, that company raised US$382.5 million on Nasdaq with this single molecule. What's worth reviewing in this deal is not the price.
Sep 26, 2026 · 13 min read→